SPRC:NASDAQSciSparc Ltd. Analysis

SciSparc Ltd. (SPRC) has rallied sharply after its subsidiary NeuroThera Labs secured a conditional regulatory green light for a $9.46 M acquisition, injecting fresh market enthusiasm. The stock now trades around $9.81, well below the DCF‑derived fair value of roughly $26.6, and its valuation multiples are minuscule (PE ≈ 0.1 vs. industry PE ≈ 27.5, PB ≈ 0.07). Technical signals are mixed: the MACD is bullish, the RSI sits at 70 indicating overbought conditions, and price remains above the identified support of $4 but below resistance near $15.7, while the trend is classified as neutral. Fundamentals are fragile: revenue has contracted 34.5%, operating margins are –8.5%, and the company posted a –$4.1 M operating cash‑flow deficit despite a modest $0.83 M free cash flow boost. Volatility is extreme at >300% over the past 30 days, beta hovers around 1.1, and the max drawdown exceeds –95%, underscoring a high‑risk profile. The balance sheet shows $4.6 M in cash against $0.37 M of debt, yielding a debt‑to‑equity ratio of 7.1, which raises concerns about capital adequacy if cash burn accelerates.
Given the speculative upside from the regulatory milestone, the stock appears markedly undervalued relative to intrinsic estimates, but the combination of weak earnings, high volatility, and biotech‑specific regulatory risk tempers enthusiasm. Investors should weigh the short‑term price momentum against the long‑term uncertainty of clinical outcomes and cash sustainability before committing capital.